{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:32:12Z","timestamp":1790699532610,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00417-008-1034-x","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T13:22:06Z","timestamp":1233580926000},"page":"735-743","source":"Crossref","is-referenced-by-count":68,"title":["Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up"],"prefix":"10.1007","volume":"247","author":[{"name":"for the Pan-American Collaborative Retina Study Group (PACORES)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Fernando","family":"Arevalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jans","family":"Fromow-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria H.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel E.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782\u2013787, doi: 10.1038\/414782a","journal-title":"Nature"},{"key":"1034_CR2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464\u20131474","journal-title":"Ophthalmology"},{"key":"1034_CR3","first-page":"331","volume-title":"Evidence-Based Ophthalmology","author":"B Richter","year":"2004","unstructured":"Richter B, Kohner E (2004) Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K (eds) Evidence-Based Ophthalmology. BMJ Books, London, pp 331\u2013340"},{"key":"1034_CR4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796\u20131806","journal-title":"Arch Ophthalmol"},{"key":"1034_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0161-6420(87)33527-4","volume":"94","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1987","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2. Ophthalmology 94:761\u2013774","journal-title":"Ophthalmology"},{"key":"1034_CR6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0039-6257(84)90227-3","volume":"28","author":"FL Ferris III","year":"1984","unstructured":"Ferris FL III, Patz A (1984) Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 28:452\u2013461, doi: 10.1016\/0039-6257(84)90227-3","journal-title":"Surv Ophthalmol"},{"key":"1034_CR7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0161-6420(83)34388-8","volume":"90","author":"GH Bresnick","year":"1983","unstructured":"Bresnick GH (1983) Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 90:1301\u20131317","journal-title":"Ophthalmology"},{"key":"1034_CR8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0161-6420(91)32082-7","volume":"98","author":"CM Lee","year":"1991","unstructured":"Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 98:1594\u201360","journal-title":"Ophthalmology"},{"key":"1034_CR9","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2004.05.025","volume":"111","author":"FK Sutter","year":"2004","unstructured":"Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044\u20132049, doi: 10.1016\/j.ophtha.2004.05.025","journal-title":"Ophthalmology"},{"key":"1034_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2003.05.037","volume":"111","author":"P Massin","year":"2004","unstructured":"Massin P, Aurden F, Houchine B, Erginy A (2004) Intravitreas triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111:218\u2013225, doi: 10.1016\/j.ophtha.2003.05.037","journal-title":"Ophthalmology"},{"key":"1034_CR11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","volume":"113","author":"MC Gillies","year":"2006","unstructured":"Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533\u20131538, doi: 10.1016\/j.ophtha.2006.02.065","journal-title":"Ophthalmology"},{"key":"1034_CR12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/jop.2006.22.200","volume":"22","author":"JB Jonas","year":"2006","unstructured":"Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH (2006) Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22:200\u2013207, doi: 10.1089\/jop.2006.22.200","journal-title":"J Ocul Pharmacol Ther"},{"key":"1034_CR13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1600-0420.2006.00700.x","volume":"84","author":"F Audren","year":"2006","unstructured":"Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84:624\u2013630, doi: 10.1111\/j.1600-0420.2006.00700.x","journal-title":"Acta Ophthalmol Scand"},{"key":"1034_CR14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","volume":"112","author":"ET Cunningham Jr","year":"2005","unstructured":"Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D\u2019Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study Group (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747\u20131757, doi: 10.1016\/j.ophtha.2005.06.007","journal-title":"Ophthalmology"},{"key":"1034_CR15","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","volume":"113","author":"DW Chun","year":"2006","unstructured":"Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706\u20131712, doi: 10.1016\/j.ophtha.2006.04.033","journal-title":"Ophthalmology"},{"key":"1034_CR16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","volume":"26","author":"C Haritoglou","year":"2006","unstructured":"Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999\u20131005, doi: 10.1097\/01.iae.0000247165.38655.bf","journal-title":"Retina"},{"key":"1034_CR17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000098504","volume":"39","author":"C Starita","year":"2007","unstructured":"Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen\u00ae) in diabetic retinopathy. Dev Ophthalmol 39:122\u2013148, doi: 10.1159\/000098504","journal-title":"Dev Ophthalmol"},{"key":"1034_CR18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611, doi: 10.1210\/er.2003-0027","journal-title":"Endocr Rev"},{"key":"1034_CR19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","volume":"14","author":"RJ Antcliff","year":"1999","unstructured":"Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223\u2013232, doi: 10.3109\/08820539909069541","journal-title":"Semin Ophthalmol"},{"key":"1034_CR20","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","volume":"110","author":"H Funatsu","year":"2003","unstructured":"Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110:1690\u20131696, doi: 10.1016\/S0161-6420(03)00568-2","journal-title":"Ophthalmology"},{"key":"1034_CR21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D\u2019Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445\u2013450","journal-title":"Am J Ophthalmol"},{"key":"1034_CR22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487, doi: 10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"key":"1034_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-9394(01)01381-2","volume":"133","author":"MJ Tolentino","year":"2002","unstructured":"Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373\u2013385, doi: 10.1016\/S0002-9394(01)01381-2","journal-title":"Am J Ophthalmol"},{"key":"1034_CR24","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","volume":"103","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820\u20131828","journal-title":"Ophthalmology"},{"key":"1034_CR25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400, doi: 10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"key":"1034_CR26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278, doi: 10.1097\/00006982-200603000-00004","journal-title":"Retina"},{"key":"1034_CR27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372, doi: 10.1016\/j.ophtha.2005.11.019","journal-title":"Ophthalmology"},{"key":"1034_CR28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","volume":"26","author":"D Iturralde","year":"2006","unstructured":"Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279\u2013284, doi: 10.1097\/00006982-200603000-00005","journal-title":"Retina"},{"key":"1034_CR29","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695,e1\u201315","journal-title":"Ophthalmology"},{"key":"1034_CR30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390, doi: 10.1097\/00006982-200604000-00001","journal-title":"Retina"},{"key":"1034_CR31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","volume":"26","author":"RM Rich","year":"2006","unstructured":"Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495\u2013511, doi: 10.1097\/01.iae.0000225766.75009.3a","journal-title":"Retina"},{"key":"1034_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2006.02.015","volume":"142","author":"Y Oshima","year":"2006","unstructured":"Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155\u2013158, doi: 10.1016\/j.ajo.2006.02.015","journal-title":"Am J Ophthalmol"},{"key":"1034_CR33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","volume":"55","author":"PK Shan","year":"2007","unstructured":"Shan PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive retinopathy of prematurity. Indian J Ophthalmol 55:75\u201376","journal-title":"Indian J Ophthalmol"},{"key":"1034_CR34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME, Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743\u2013750, doi: 10.1016\/j.ophtha.2006.12.028","journal-title":"Ophthalmology"},{"key":"1034_CR35","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","volume":"115","author":"Diabetic Retinopathy Clinical Reseach Network","year":"2008","unstructured":"Diabetic Retinopathy Clinical Reseach Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447\u20131449, doi: 10.1016\/j.ophtha.2008.06.015","journal-title":"Ophthalmology"},{"key":"1034_CR36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329:977\u2013986, doi: 10.1056\/NEJM199309303291401","journal-title":"N Engl J Med"},{"key":"1034_CR37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703\u2013713","journal-title":"BMJ"},{"key":"1034_CR38","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1167\/iovs.05-0096","volume":"46","author":"C Strom","year":"2005","unstructured":"Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M (2005) Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 46:3855\u20133858, doi: 10.1167\/iovs.05-0096","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1034_CR39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1167\/iovs.03-0955","volume":"45","author":"PA Campochiaro","year":"2004","unstructured":"Campochiaro PA, C99-PKC412-003 Study Group (2004) Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45:922\u2013931, doi: 10.1167\/iovs.03-0955","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1034_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/0301-4738.36481","volume":"55","author":"A Kumar","year":"2007","unstructured":"Kumar A, Sinha S (2007) Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 55:451\u2013455","journal-title":"Indian J Ophthalmol"},{"key":"1034_CR41","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199\u20132205, doi: 10.1016\/j.ophtha.2008.07.007","journal-title":"Ophthalmology"},{"key":"1034_CR42","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0161-6420(03)01004-2","volume":"110","author":"AP Schachat","year":"2003","unstructured":"Schachat AP, Chambers WA, Liesegang TJ, Albert DA (2003) Safe and effective. Ophthalmology 110:2073\u20132074, doi: 10.1016\/S0161-6420(03)01004-2","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-1034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-008-1034-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-1034-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:13Z","timestamp":1633046413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-008-1034-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,3]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1007\/s00417-008-1034-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,3]]}}}